SCHEMBL567527

SCHEMBL567527

C1CC2C[N]CC1CN2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL567378 0.77
Isoquinuclidine SCHEMBL15192831 0.72
Isoquinuclidine SCHEMBL23982869 0.72
Isoquinuclidine SCHEMBL27542 0.72
Isoquinuclidine SCHEMBL2581763 0.69
SCHEMBL245466 0.67
SCHEMBL19951622 0.67
SCHEMBL417278 0.67
SCHEMBL13645939 0.67
SCHEMBL4146707 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4363421-A1 IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2024-05-08 EP disclosed
US-20240140951-A1 IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2024-05-02 US disclosed
EP-4259631-A1 IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2023-10-18 EP disclosed
US-20230271951-A1 DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) 2023-08-31 US disclosed
EP-4132650-A1 DIFLUOROCYCLOHEXYL DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2023-02-15 EP disclosed
WO-2023275301-A1 IMIDAZOTRIAZINE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2023-01-05 WO disclosed
WO-2022128584-A1 IMIDAZOPYRIDAZINE DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2022-06-23 WO disclosed
WO-2022096411-A1 DICYCLOPROPYLMETHYL DERIVATIVES AS IL-17 MODULATORS UCB Biopharma SRL (BE) 2022-05-12 WO disclosed
US-20180298009-A1 Fused Pyrazole Derivatives As Kinase Inhibitors UCB BIOPHARMA SPRL (BE) 2018-10-18 US disclosed
US-20180273525-A1 Fused Pyridine Derivatives As Kinase Inhibitors UCB BIOPHARMA SPRL (BE) 2018-09-27 US disclosed
EP-3356365-A1 FUSED PYRIDINE DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SPRL (BE) 2018-08-08 EP disclosed
EP-3356367-A1 FUSED PYRAZOLE DERIVATIVES AS KINASE INHIBITORS UCB Biopharma SPRL (BE) 2018-08-08 EP disclosed
EP-2444395-B1 SUBSTITUTED ISOQUINOLINE DERIVATIVE WESTERN THERAPEUTICS INST INC D (JP) 2016-01-06 EP disclosed
US-8951997-B2 Substituted isoquinoline derivative D. WESTERN THERAPEUTICS INSTITUTE, INC. (JP) 2015-02-10 US disclosed
EP-2444395-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. Western Therapeutics Institute, Inc. (JP) 2012-04-25 EP disclosed
US-20120035159-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVE D. WESTERN THERAPEUTICS INSTITUTE, INC (JP) 2012-02-09 US disclosed
US-6153608-A Isoquinoline derivatives and drugs NIPPON SHINYAKU CO., LTD. (JP) 2000-11-28 US disclosed
EP-0885888-A1 ISOQUINOLINE DERIVATIVES AND DRUGS NIPPON SHINYAKU COMPANY, LIMITED (JP) 1998-12-23 EP disclosed
WO-1996004254-A2 BENZODIAZEPINE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-02-15 WO disclosed